S&P 500   3,821.35 (-0.54%)
DOW   31,802.44 (+0.97%)
QQQ   300.30 (-2.71%)
AAPL   116.54 (-4.02%)
MSFT   227.60 (-1.73%)
FB   255.73 (-3.24%)
GOOGL   2,012.94 (-4.01%)
TSLA   565.24 (-5.47%)
AMZN   2,957.35 (-1.44%)
NVDA   465.42 (-6.63%)
BABA   226.69 (-3.08%)
CGC   30.99 (-0.58%)
GE   14.16 (+4.12%)
MU   85.27 (-4.12%)
NIO   35.21 (-7.61%)
AMD   74.08 (-5.65%)
T   30.05 (+1.45%)
F   12.65 (+3.10%)
ACB   9.62 (+0.21%)
DIS   202.87 (+6.78%)
BA   224.34 (+0.50%)
NFLX   494.10 (-4.32%)
PFE   34.39 (+0.00%)
S&P 500   3,821.35 (-0.54%)
DOW   31,802.44 (+0.97%)
QQQ   300.30 (-2.71%)
AAPL   116.54 (-4.02%)
MSFT   227.60 (-1.73%)
FB   255.73 (-3.24%)
GOOGL   2,012.94 (-4.01%)
TSLA   565.24 (-5.47%)
AMZN   2,957.35 (-1.44%)
NVDA   465.42 (-6.63%)
BABA   226.69 (-3.08%)
CGC   30.99 (-0.58%)
GE   14.16 (+4.12%)
MU   85.27 (-4.12%)
NIO   35.21 (-7.61%)
AMD   74.08 (-5.65%)
T   30.05 (+1.45%)
F   12.65 (+3.10%)
ACB   9.62 (+0.21%)
DIS   202.87 (+6.78%)
BA   224.34 (+0.50%)
NFLX   494.10 (-4.32%)
PFE   34.39 (+0.00%)
S&P 500   3,821.35 (-0.54%)
DOW   31,802.44 (+0.97%)
QQQ   300.30 (-2.71%)
AAPL   116.54 (-4.02%)
MSFT   227.60 (-1.73%)
FB   255.73 (-3.24%)
GOOGL   2,012.94 (-4.01%)
TSLA   565.24 (-5.47%)
AMZN   2,957.35 (-1.44%)
NVDA   465.42 (-6.63%)
BABA   226.69 (-3.08%)
CGC   30.99 (-0.58%)
GE   14.16 (+4.12%)
MU   85.27 (-4.12%)
NIO   35.21 (-7.61%)
AMD   74.08 (-5.65%)
T   30.05 (+1.45%)
F   12.65 (+3.10%)
ACB   9.62 (+0.21%)
DIS   202.87 (+6.78%)
BA   224.34 (+0.50%)
NFLX   494.10 (-4.32%)
PFE   34.39 (+0.00%)
S&P 500   3,821.35 (-0.54%)
DOW   31,802.44 (+0.97%)
QQQ   300.30 (-2.71%)
AAPL   116.54 (-4.02%)
MSFT   227.60 (-1.73%)
FB   255.73 (-3.24%)
GOOGL   2,012.94 (-4.01%)
TSLA   565.24 (-5.47%)
AMZN   2,957.35 (-1.44%)
NVDA   465.42 (-6.63%)
BABA   226.69 (-3.08%)
CGC   30.99 (-0.58%)
GE   14.16 (+4.12%)
MU   85.27 (-4.12%)
NIO   35.21 (-7.61%)
AMD   74.08 (-5.65%)
T   30.05 (+1.45%)
F   12.65 (+3.10%)
ACB   9.62 (+0.21%)
DIS   202.87 (+6.78%)
BA   224.34 (+0.50%)
NFLX   494.10 (-4.32%)
PFE   34.39 (+0.00%)
Log in
NASDAQ:EIDX

Eidos Therapeutics Stock Forecast, Price & News

Notice: This company has been marked as potentially delisted and may not be actively trading.
$122.21
0.00 (0.00 %)
(As of 01/26/2021)
Add
Compare
Today's Range
$122.21
Now: $122.21
$122.21
50-Day Range
$120.98
MA: $123.21
$128.51
52-Week Range
$28.39
Now: $122.21
$132.54
VolumeN/A
Average Volume128,113 shs
Market Capitalization$4.75 billion
P/E RatioN/A
Dividend YieldN/A
Beta-0.16
Eidos Therapeutics, Inc., a clinical stage biopharmaceutical company, focuses on developing drugs to treat diseases caused by transthyretin (TTR) or amyloidosis (ATTR). It is developing AG10, which is in phase 3 clinical trial, is an orally-administered small molecule designed to stabilize tetrameric TTR, thereby halting at its outset the series of molecular events that give rise to ATTR. The company was founded in 2013 and is headquartered in San Francisco, California. Eidos Therapeutics, Inc. is a subsidiary of BridgeBio Pharma, Inc.
Eidos Therapeutics logo

Headlines

Is EIDX A Good Stock To Buy Now?
December 14, 2020 |  finance.yahoo.com
See More Headlines

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:EIDX
CUSIPN/A
CIKN/A
Phone415-887-1471
Employees70
Year FoundedN/A

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$26.69 million
Book Value$4.57 per share

Profitability

Net Income$-37,830,000.00

Miscellaneous

Market Cap$4.75 billion
Next Earnings DateN/A
OptionableNot Optionable

MarketRank

Overall MarketRank

0.99 out of 5 stars

Medical Sector

1040th out of 1,968 stocks

Pharmaceutical Preparations Industry

473rd out of 771 stocks

Analyst Opinion: 1.0Community Rank: 2.3Dividend Strength: 0.0Insider Behavior: 1.7Valuation: 0.0 5 -4 -3 -2 -1 -

Receive EIDX News and Ratings via Email

Sign-up to receive the latest news and ratings for EIDX and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











Eidos Therapeutics (NASDAQ:EIDX) Frequently Asked Questions

Is Eidos Therapeutics a buy right now?

10 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Eidos Therapeutics in the last year. There are currently 1 sell rating, 8 hold ratings and 1 buy rating for the stock. The consensus among Wall Street research analysts is that investors should "hold" Eidos Therapeutics stock. A hold rating indicates that analysts believe investors should maintain any existing positions they have in EIDX, but not buy additional shares or sell existing shares.
View analyst ratings for Eidos Therapeutics
or view top-rated stocks.

What stocks does MarketBeat like better than Eidos Therapeutics?

Wall Street analysts have given Eidos Therapeutics a "Hold" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Eidos Therapeutics wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

How were Eidos Therapeutics' earnings last quarter?

Eidos Therapeutics, Inc. (NASDAQ:EIDX) released its quarterly earnings data on Thursday, October, 29th. The company reported ($0.79) earnings per share (EPS) for the quarter, missing the Thomson Reuters' consensus estimate of ($0.71) by $0.08. The firm had revenue of $0.13 million for the quarter.
View Eidos Therapeutics' earnings history
.

What price target have analysts set for EIDX?

10 equities research analysts have issued 1-year price targets for Eidos Therapeutics' shares. Their forecasts range from $34.00 to $73.26. On average, they anticipate Eidos Therapeutics' stock price to reach $53.45 in the next twelve months. This suggests that the stock has a possible downside of 56.3%.
View analysts' price targets for Eidos Therapeutics
or view top-rated stocks among Wall Street analysts.

Who are Eidos Therapeutics' key executives?

Eidos Therapeutics' management team includes the following people:
  • Dr. Neil Kumar, CEO & Director (Age 42, Pay $247.68k)
  • Dr. Uma Sinha, Chief Scientific Officer & Director (Age 64, Pay $533.4k)
  • Dr. Cameron Turtle DPHIL, Ph.D., Chief Bus. Officer (Age 31, Pay $578.4k)
  • Dr. Jonathan C. Fox FACC, M.D., Ph.D., Pres & Chief Medical Officer (Age 64)
  • Dr. Isabella Graef M.D., Co-Founder & Board Advisor (Age 56)
  • Dr. Mamoun Alhamadsheh Ph.D., Pharm.D., Co-Founder
  • Mr. Franco Valle, Sr. VP of Fin., Principal Accounting Officer & Sec. (Age 40)
  • Mr. Matt Outten, Chief Commercial Officer
  • Dr. Hoyoung Huh, Consultant (Age 52)

Who are some of Eidos Therapeutics' key competitors?

What other stocks do shareholders of Eidos Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Eidos Therapeutics investors own include Exelixis (EXEL), CRISPR Therapeutics (CRSP), Aduro Biotech (ADRO), Micron Technology (MU), Pfizer (PFE), Verastem (VSTM), ImmunoGen (imgn), Nabriva Therapeutics (NBRV), Occidental Petroleum (OXY) and Axsome Therapeutics (AXSM).

When did Eidos Therapeutics IPO?

(EIDX) raised $101 million in an initial public offering on Wednesday, June 20th 2018. The company issued 6,300,000 shares at $15.00-$17.00 per share. J.P. Morgan and BofA Merrill Lynch acted as the underwriters for the IPO and Barclays was co-manager.

What is Eidos Therapeutics' stock symbol?

Eidos Therapeutics trades on the NASDAQ under the ticker symbol "EIDX."

Who are Eidos Therapeutics' major shareholders?

Eidos Therapeutics' stock is owned by many different institutional and retail investors. Top institutional investors include BlackRock Inc. (4.01%), Magnetar Financial LLC (1.54%), Price T Rowe Associates Inc. MD (0.54%), American International Group Inc. (0.53%), Alpine Associates Management Inc. (0.47%) and Lord Abbett & CO. LLC (0.46%). Company insiders that own Eidos Therapeutics stock include Bridgebio Pharma, Inc, Cameron Turtle, Christine Siu, Eric Aguiar, Franco Valle, Jonathan C Fox and Uma Sinha.
View institutional ownership trends for Eidos Therapeutics
.

Which major investors are selling Eidos Therapeutics stock?

EIDX stock was sold by a variety of institutional investors in the last quarter, including Candriam Luxembourg S.C.A., Victory Capital Management Inc., Aviva PLC, Charles Schwab Investment Management Inc., Principal Financial Group Inc., Virtus ETF Advisers LLC, Strs Ohio, and Wells Fargo & Company MN. Company insiders that have sold Eidos Therapeutics company stock in the last year include Cameron Turtle, Franco Valle, Jonathan C Fox, and Uma Sinha.
View insider buying and selling activity for Eidos Therapeutics
or view top insider-selling stocks.

Which major investors are buying Eidos Therapeutics stock?

EIDX stock was bought by a variety of institutional investors in the last quarter, including Magnetar Financial LLC, Alpine Associates Management Inc., Tudor Investment Corp Et Al, Spring Creek Capital LLC, Citigroup Inc., Chicago Capital Management LLC, Alliancebernstein L.P., and Healthcare of Ontario Pension Plan Trust Fund. Company insiders that have bought Eidos Therapeutics stock in the last two years include Bridgebio Pharma, Inc, and Eric Aguiar.
View insider buying and selling activity for Eidos Therapeutics
or or view top insider-buying stocks.

What is Eidos Therapeutics' stock price today?

One share of EIDX stock can currently be purchased for approximately $122.21.

How much money does Eidos Therapeutics make?

Eidos Therapeutics has a market capitalization of $4.75 billion and generates $26.69 million in revenue each year. The company earns $-37,830,000.00 in net income (profit) each year or ($1.03) on an earnings per share basis.

How many employees does Eidos Therapeutics have?

Eidos Therapeutics employs 70 workers across the globe.

What is Eidos Therapeutics' official website?

The official website for Eidos Therapeutics is www.eidostx.com.

Where are Eidos Therapeutics' headquarters?

Eidos Therapeutics is headquartered at 101 MONTGOMERY STREET SUITE 2550, SAN FRANCISCO CA, 94104.

How can I contact Eidos Therapeutics?

Eidos Therapeutics' mailing address is 101 MONTGOMERY STREET SUITE 2550, SAN FRANCISCO CA, 94104. The company can be reached via phone at 415-887-1471 or via email at [email protected]


This page was last updated on 3/8/2021 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.